DA-EPOCH-R appears more toxic than standard R-CHOP in DLBCLApril 5, 2019Lymphoma & Plasma Cell Disorders
Polatuzumab outperforms pinatuzumab in non-Hodgkin lymphomaApril 5, 2019Lymphoma & Plasma Cell Disorders
Early data support R-BAC for post-BTKi mantle cell lymphomaApril 5, 2019Lymphoma & Plasma Cell Disorders
ASCO, CCO issue multiple myeloma treatment guidelinesApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Real world responses mirror TOURMALINE-MM1 dataApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Whole-genome sequencing demonstrates clinical relevanceApril 4, 2019AMLALLLeukemia, Myelodysplasia, Transplantation
Combo could replace standard conditioning regimen for myelomaApril 2, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Ibrutinib sustained responses in refractory CLL in long-term follow-upMarch 27, 2019Leukemia, Myelodysplasia, Transplantation
High survival in relapsed FL after primary radiotherapyMarch 21, 2019Lymphoma & Plasma Cell Disorders
